One of the most significant – and relatively recent – innovations in the treatment of cancer are so-called immuno-oncology (IO) drugs. As today’s article explains, these drugs “enlist a patient’s immune system in the fight, giving it marching orders to tackle cancer cells…Under the right circumstances, the best IO performers can make traditional chemotherapy or surgery far more effective, or potentially even replace them”. For more on the potential of IO drugs to become “miracle” treatments for a range of cancers – and some pharmaceutical companies experiencing early success in the space – CLICK HERE.
More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
With only 10% of drug candidates that reach the clinical trial stage eventually making their way onto the market, knowing which small biotechs to bet on for big gains is no easy feat for investors. The author of today’s article suggests that one way investors can increase their odds of success is by identifying small biotechs that are getting the attention (and money) of big pharma companies. He proceeds to highlight one such company, which “has developed an innovative product that makes other drugs more effective” – attracting capital from the likes of Roche, Johnson & Johnson and more. To read about this company, the science behind its technology – and the opportunity for investors – CLICK HERE.